Announcements Trials
Browse Landscape

Phase

Phase 1 5Phase 2/3 2Phase 2 1Phase 1/2 1

Status

Completed 5

Sponsor Class

INDUSTRY 4OTHER 1

Study Type

Interventional 5

Sponsor

Cancer Type

Other solid neoplasm 1

Conditions

Advanced Cancer 4Solid Tumor 1

Interventions

Cyclophosphamide 626pembrolizumab 505Paclitaxel 456Gemcitabine 439Carboplatin 437Cisplatin 420Radiotherapy 382fludarabine 367Nivolumab 340Docetaxel 278Bevacizumab 276Irinotecan 258Magnetic Resonance Spectroscopy 245Fluorouracil 229Dexamethasone 225Specimen Handling 223Capecitabine 218Rituximab 206Oxaliplatin 201Cytarabine 201Ipilimumab 198Temozolomide 197Biopsy 197fludarabine phosphate 194Etoposide 181Lenalidomide 176Doxorubicin 175Leucovorin 174Cetuximab 171Injections 170

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
Phase 1 × Interventional × ARRY-334543 × Clear all
NCT00278902 2020-10-14

A Study of ARRY-334543 in Patients With Advanced Cancer

Array BioPharma

Phase 1 Completed
96 enrolled

Advanced Cancer

NCT00637702 2020-10-08

A Study of ARRY-334543 in Patients With Advanced Cancer

Array BioPharma

Phase 1 Completed
31 enrolled

Advanced Cancer

NCT00710736 2020-10-06

A Study of ARRY-334543 and Capecitabine in Patients With Advanced Cancer

Array BioPharma

Phase 1 Completed
29 enrolled

Advanced Cancer

NCT00833326 2020-10-06

A Study of ARRY-334543 and Docetaxel in Patients With Advanced Cancer

Array BioPharma

Phase 1 Completed
27 enrolled

Advanced Cancer

NCT02648425 2018-10-25

Safety and Tolerability of ASLAN001 in Combination With Cisplatin and 5-FU or Cisplatin and Capecitabine

ASLAN Pharmaceuticals

Phase 1 Completed
31 enrolled
Other solid neoplasm

Solid Tumor

Data powered by HemOnc (CC BY 4.0) Colophon âš¡